Corcept Shifts Endocrinology Leadership Amid Cushing’s Syndrome Expansion
Event summary
- Sean Maduck, President of Corcept’s Endocrinology division, to retire effective October 1, 2026.
- Justin Gunn, former VP of Sales and Commercial Learning for Oncology, promoted to succeed Maduck.
- Maduck to remain as senior commercial advisor to ensure smooth transition.
- Gunn previously led commercial teams at Gilead Sciences, Merck, and Sepracor.
The big picture
Corcept’s leadership transition comes as the company seeks to broaden its reach in treating Cushing’s syndrome, a niche but growing endocrinology market. The shift reflects a strategic pivot toward leveraging commercial expertise from other therapeutic areas to drive growth. With multiple clinical trials underway, the company’s ability to maintain momentum in its core endocrinology business will be critical.
What we're watching
- Commercial Execution
- How Justin Gunn’s experience in oncology will translate to endocrinology leadership.
- Patient Expansion
- Whether Corcept can capitalize on growing awareness of Cushing’s syndrome to expand its patient base.
- Pipeline Progress
- The pace at which Corcept advances its clinical trials in hypercortisolism, ALS, and liver disease.
Related topics